SCHEMBL2870441

SCHEMBL2870441

O=C1c2ccccc2C(=O)c2c1ccc(S(=O)(=O)O)c2O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGAM1 P18669 5/20 0.68
MAPT P10636 7/20 0.62
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
ALDH1A1 P00352 4/20 0.62
MAOA P21397 4/20 0.62
MCL1 Q07820 3/20 0.62
HSD17B10 Q99714 3/20 0.62
MAPK1 P28482 3/20 0.62
DAPK1 P53355 3/20 0.62
BCL2 P10415 2/20 0.62
KDM4E B2RXH2 2/20 0.62
CYP3A4 P08684 2/20 0.62
HPGD P15428 2/20 0.62
ALOX15 P16050 2/20 0.62
ALOX12 P18054 2/20 0.62
RECQL P46063 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
CYP1B1 Q16678 2/20 0.62
APEX1 P27695 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27939359 0.98 PGAM1 (0.66) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL6905576 0.91 PGAM1 (0.53) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL6901828 0.89 PGAM1 (0.51) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL16950304 0.87 PGAM1 (0.50) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL17038036 0.86 MAOA (0.63) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL17038035 0.85 MAOA (0.65) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL159669 0.84 PGAM1 (0.56) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL29643579 0.84 PGAM1 (0.56) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL17494572 0.83 PGAM1 (0.52) PGAM1MAPTMEN1KMT2AALDH1A1
SCHEMBL5246506 0.82 PGAM1 (0.54) PGAM1MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-20210154213-A1 PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES CALASIA PHARMACEUTICALS INC (US) 2021-05-27 US disclosed
EP-2098582-B1 FUNCTIONAL ELECTRODE AND FUNCTIONAL ELECTROCHROMIC DEVICE RICOH CO LTD (JP) 2017-12-06 EP disclosed
US-7830584-B2 Organic-inorganic composite material and method for producing the same, and functional electrode and functional device RICOH COMPANY, LTD. (JP) 2010-11-09 US disclosed
US-7759045-B2 Chemically amplified positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-20 US disclosed
EP-2098582-A1 ORGANIC INORGANIC COMPOSITE MATERIAL, PROCESS FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRODE AND FUNCTIONAL DEVICE Ricoh Company, Ltd. (JP) 2009-09-09 EP disclosed
US-7489432-B2 Electrochromic display device and display apparatus RICOH COMPANY, LTD. (JP) 2009-02-10 US disclosed
US-20090004601-A1 Chemically amplified positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-01 US disclosed
US-20090002802-A1 ORGANIC-INORGANIC COMPOSITE MATERIAL AND METHOD FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRODE AND FUNCTIONAL DEVICE RICOH COMPANY, LTD. (JP) 2009-01-01 US disclosed
US-20060215250-A1 Electrochromic display device and display apparatus RICOH COMPANY, LTD. (JP) 2006-09-28 US disclosed
US-4014906-A Process for the manufacture of anthraquinone compounds CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed
US-3983145-A Use of alpha-di(lower alkoxy) anthraquinones in the synthesis of Alizarin Saphirols TOMS RIVER CHEMICAL CORPORATION (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210154213-A1 PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES CRYAA, CRYAB, TTR PGAM1 2336/4885MAPT 14/4885MEN1 3695/4885
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR PGAM1 2336/4885MAPT 14/4885MEN1 3695/4885
US-20090002802-A1 ORGANIC-INORGANIC COMPOSITE MATERIAL AND METHOD FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRODE AND FUNCTIONAL DEVICE EPCAM, ILK, L1CAM PGAM1 3651/4885MAPT 2202/4885MEN1 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.